Literature DB >> 11692036

Monocyte chemoattractant protein-1 is increased in the cerebrospinal fluid of patients with ischemic stroke.

J Losy1, J Zaremba.   

Abstract

BACKGROUND AND
PURPOSE: Animal models of stroke have shown that focal cerebral ischemia results in an increased expression of several cytokines and chemokines that precedes leukocyte infiltration into ischemic lesions. The infiltrated leukocytes are thought to contribute to tissue injury in stroke. Monocyte chemoattractant protein-1 (MCP-1) may play an important role in monocyte/macrophage infiltration in stroke patients.
METHODS: We studied MCP-1 level in sera and the cerebrospinal fluid of 23 ischemic stroke patients 24 hours after the onset of neurological symptoms and compared the results with 15 control patients with tension headache. The MCP-1 level was determined by ELISA.
RESULTS: There was a significant increase of cerebrospinal fluid MCP-1 level in the studied stroke patients in comparison with the control group. The serum level of MCP-1 did not differ from that of control patients.
CONCLUSIONS: Our results suggest that MCP-1 may play a role in the inflammatory reaction during the early phase of ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11692036     DOI: 10.1161/hs1101.097380

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  44 in total

Review 1.  Human cellular inflammation in the pathology of acute cerebral ischaemia.

Authors:  C J S Price; E A Warburton; D K Menon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-11       Impact factor: 10.154

2.  Inflammation after stroke: mechanisms and therapeutic approaches.

Authors:  Muzamil Ahmad; Steven H Graham
Journal:  Transl Stroke Res       Date:  2010-06       Impact factor: 6.829

Review 3.  Molecular dialogs between the ischemic brain and the peripheral immune system: dualistic roles in injury and repair.

Authors:  Chengrui An; Yejie Shi; Peiying Li; Xiaoming Hu; Yu Gan; Ruth A Stetler; Rehana K Leak; Yanqin Gao; Bao-Liang Sun; Ping Zheng; Jun Chen
Journal:  Prog Neurobiol       Date:  2013-12-26       Impact factor: 11.685

Review 4.  Neuroimmune interaction in seizures and epilepsy: focusing on monocyte infiltration.

Authors:  Dale B Bosco; Dai-Shi Tian; Long-Jun Wu
Journal:  FEBS J       Date:  2020-06-15       Impact factor: 5.542

5.  Altered hippocampal synaptic transmission in transgenic mice with astrocyte-targeted enhanced CCL2 expression.

Authors:  Thomas E Nelson; Christine Hao; Jessica Manos; R M Ransohoff; Donna L Gruol
Journal:  Brain Behav Immun       Date:  2011-02-26       Impact factor: 7.217

Review 6.  Role of MCP-1 and CCR2 in alcohol neurotoxicity.

Authors:  Kai Zhang; Jia Luo
Journal:  Pharmacol Res       Date:  2018-11-22       Impact factor: 7.658

7.  Synaptic plasticity in the hippocampus shows resistance to acute ethanol exposure in transgenic mice with astrocyte-targeted enhanced CCL2 expression.

Authors:  Jennifer G Bray; Kenneth C Reyes; Amanda J Roberts; Richard M Ransohoff; Donna L Gruol
Journal:  Neuropharmacology       Date:  2012-11-16       Impact factor: 5.250

Review 8.  Mechanisms in blood-brain barrier opening and metabolism-challenged cerebrovascular ischemia with emphasis on ischemic stroke.

Authors:  Sajad Sarvari; Faezeh Moakedi; Emily Hone; James W Simpkins; Xuefang Ren
Journal:  Metab Brain Dis       Date:  2020-04-15       Impact factor: 3.584

Review 9.  Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks.

Authors:  Bridgette D Semple; Thomas Kossmann; Maria Cristina Morganti-Kossmann
Journal:  J Cereb Blood Flow Metab       Date:  2009-11-11       Impact factor: 6.200

10.  CD38 exacerbates focal cytokine production, postischemic inflammation and brain injury after focal cerebral ischemia.

Authors:  Chi-un Choe; Kerstin Lardong; Mathias Gelderblom; Peter Ludewig; Frank Leypoldt; Friedrich Koch-Nolte; Christian Gerloff; Tim Magnus
Journal:  PLoS One       Date:  2011-05-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.